Abstract: Disclosed is an electronic apparatus, including: a storage; and a processor configured to execute a first execution code based on first configuration information in response to an execution event of a program including the first execution code and the first configuration information stored in the storage, update the program by replacing the first execution code and the first configuration information with a second execution code and second configuration information in response to an update event of the program, and update the first configuration information to the second configuration information while maintaining the first execution code in response to the update event of the first configuration information.

Abstract: Antagonistic small-molecule compounds having a function of inhibiting endosomal Toll-like receptors (TLRs), more specifically, a small-molecule compound for inhibiting TLR3/7/8/9 signaling pathways, a composition for inhibiting Toll-like receptors, containing the compound; and a composition for preventing or treating autoimmune diseases, inflammatory diseases, or viral diseases are disclosed. The novel compound shows very significant results in a systemic lupus erythematosus animal model by not only preventing TNF-? secretion induced by poly I:C (TLR3 agonist), imiquimod (TLR7 agonist), TL8-506 (TLR8 agonist), or ODN2395 (TLR9 agonist), but also inhibiting the production of inflammatory cytokines. This suggests that the compound is also useful for the prevention or treatment of TLR3, TLR7, TLR8 or TLR9-associated autoimmune diseases, inflammatory diseases and viral diseases.